Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-03-09
- Last Posted Date
- 2021-06-18
- Lead Sponsor
- Siddhartha Ganguly
- Target Recruit Count
- 101
- Registration Number
- NCT02703779
- Locations
- 🇺🇸
The University of Kansas Medical Center, Westwood, Kansas, United States
© Copyright 2024. All Rights Reserved by MedPath